Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $39.00 Average Price Target from Brokerages

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have received a consensus rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $39.00.

Several analysts have commented on AKRO shares. HC Wainwright increased their target price on Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Friday, March 1st. UBS Group increased their target price on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th.

Akero Therapeutics Stock Up 3.3 %

Shares of NASDAQ:AKRO opened at $25.26 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 29.27 and a current ratio of 29.27. The firm has a market capitalization of $1.42 billion, a P/E ratio of -8.86 and a beta of -0.37. The stock has a 50 day moving average price of $24.20 and a 200-day moving average price of $24.64. Akero Therapeutics has a 52-week low of $11.25 and a 52-week high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.17). As a group, equities research analysts anticipate that Akero Therapeutics will post -4.06 EPS for the current fiscal year.

Insider Activity at Akero Therapeutics

In related news, insider Catriona Yale sold 20,646 shares of Akero Therapeutics stock in a transaction on Monday, March 4th. The shares were sold at an average price of $35.49, for a total transaction of $732,726.54. Following the transaction, the insider now owns 78,415 shares in the company, valued at approximately $2,782,948.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Akero Therapeutics news, insider Catriona Yale sold 20,646 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $35.49, for a total value of $732,726.54. Following the sale, the insider now owns 78,415 shares in the company, valued at approximately $2,782,948.35. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 75,000 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.87, for a total transaction of $2,465,250.00. Following the transaction, the chief executive officer now directly owns 591,416 shares of the company’s stock, valued at approximately $19,439,843.92. The disclosure for this sale can be found here. 9.69% of the stock is owned by corporate insiders.

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKRO. Headlands Technologies LLC purchased a new position in Akero Therapeutics during the fourth quarter valued at approximately $28,000. Point72 Hong Kong Ltd acquired a new stake in Akero Therapeutics in the first quarter valued at approximately $32,000. KBC Group NV acquired a new stake in Akero Therapeutics in the fourth quarter valued at approximately $36,000. Quarry LP boosted its stake in Akero Therapeutics by 40.0% in the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after acquiring an additional 500 shares in the last quarter. Finally, Strs Ohio boosted its stake in Akero Therapeutics by 100.0% in the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after acquiring an additional 1,000 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.